New antibody combo targets Hard-to-Treat cancers in early trial
NCT ID NCT06932952
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new antibody called BYON4228, given alone or with the immunotherapy drug pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The study includes only 7 participants and aims to check safety, side effects, and whether the tumors shrink. It is too early to know if this approach will work, but it may lead to better options for hard-to-treat cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BYON4228 (a lab-made antibody) and pembrolizumab (an immunotherapy drug)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 7 participants, so it is too small to prove effectiveness. The treatment may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIOCC Hospital Universitario HM Sanchinarro
Madrid, Spain
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
-
Institut Jules Bordet
Brussels, Belgium
-
The Christie NHS Foundation Trust
Manchester, United Kingdom
-
The Royal Marsden
Sutton, United Kingdom
-
UZ Leuven
Leuven, Belgium